Axid (nizatidine)

The manufacturer states that nizatidine dosage adjustment based solely on age is not necessary in geriatric patients; however, dosage adjustment is required in the presence of moderate to severe renal impairment.

In patients with moderate to severe renal impairment, doses and/or frequency of administration of nizatidine should be modified in response to the degree of renal impairment. Modification of dosage in these patients may avoid excess accumulation of the drug; however, clinical efficacy of the following dosage regimens has not been systematically evaluated. For the treatment of acute duodenal ulcer, benign gastric ulcer, or gastroesophageal reflux disease in patients with creatinine clearances of 20-50 mL/minute, the manufacturer recommends a nizatidine dosage of 150 mg daily; in patients with creatinine clearances less than 20 mL/minute, a dosage of 150 mg every other day is recommended. For maintenance therapy in patients with duodenal ulcer, the manufacturer recommends a nizatidine dosage of 150 mg every other day in patients with creatinine clearances of 20-50 mL/minute; a dosage of 150 mg every 3 days is recommended in patients with creatinine clearances less than 20 mL/minute.

Reduction of nizatidine dosage in patients with hepatic impairment does not appear to be necessary.

Nizatidine is administered orally. Concomitant administration of nizatidine and food increases area under the plasma concentration-time curve (AUC) and peak plasma concentrations of the drug by 10% or less. Therefore, nizatidine generally can be given orally without regard to meals. Antacids may be administered concomitantly as necessary for relief of pain.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Reproductive studies in rats and rabbits using oral nizatidine dosages up to 1500 and 275 mg/kg daily (40.5 and 14.6 times the recommended human dose based on body surface area), respectively, have not revealed evidence of harm to the fetus. However, there are no adequate and controlled studies using nizatidine in pregnant women, and the drug should be used during pregnancy only when clearly needed. Women who are pregnant or nursing should seek the advice of a health professional before using nizatidine for self-medication.

Nizatidine is distributed into milk in rats, and growth depression has occurred in the offspring of lactating rats treated with the drug. Nizatidine also is distributed into milk in humans. Because of the potential for serious adverse reactions to nizatidine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

No enhanced messaging available.